**(1)      CIMYM, Inc.**

**(2)      CIMAB S.A.**

**And**

**(3)      Oncoscience AG**

----

**Amended      and Restated**

**Development      and Licence Agreement**

**Relating      to TheraCIM h-R3**

----

----

**Development      and Licence Agreement**

**This      Amended and Restated Development and Licence Agreement**

| (1) | **CIMYM,                Inc.**                (company registration number 12142) (“CIMYM”), a company incorporated in                Barbados, whose principal place of business is at Sagicor Centre,                Wildey,                St. Michael, Barbados, West Indies;                and |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (2) | **CIMAB                S.A.**                (company registration number 107/92) (“CIMAB”), a company incorporated in                Cuba, whose principal place of business is at 206 Street, No. 1926,                e/ 19                y 21, Atabey, Playa, Havana City, Cuba;                and |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (3) | **Oncoscience                AG**                (company registration number HRB 5414) (“Oncoscience”) a company                incorporated in Germany, whose principal place of business is at                Hafenstraße                32, 22880                Wedel, Germany. |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**Recitals:**

| A. | The                Parties entered into a development and licence agreement dated 17                November                2003 (the “Original Agreement”). |
|----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| B. | The                Parties wish to enter into this Agreement for the purposes of wholly                replacing and superseding the Original                Agreement. |
|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| C. | CIMYM                is the exclusive licensee of certain Licensed Patent Rights, certain                Licensed Know-how (each as defined below) relating to an antibody                known as                TheraCIM h-R3 (as defined below). |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| D. | The                shareholders of CIMYM are YM Biosciences, Inc. and                CIMAB. |
|----|---------------------------------------------------------------------------------------------|

| E. | CIMAB                enters into commercial agreements on behalf of the Center of Molecular                Immunology (“CIM”, as defined below). CIM originally developed TheraCIM                h-R3 and has the facilities to manufacture Licensed Products (as                defined                below). CIMAB is entering into this Agreement principally in order                to                assume the manufacturing and supply obligations set out in Clause                5. |
|----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| F. | Oncoscience                has expertise in cancer immunotherapy and experience in conducting                immunotherapy clinical trials in cancer                patients. |
|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| G. | Oncoscience                wishes to pursue the further development and commercialisation of                TheraCIM                h-R3 for the treatment of cancer in humans, in accordance with the                provisions of this Agreement. |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| H. | CIMYM                is willing to grant to Oncoscience, and Oncoscience is willing to                accept,                a licence in the Field under the Licensed Patent Rights and to use                the                Licensed Know-how, all in accordance with the provisions of this                Agreement. |
|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

**It      is agreed as follows:**

**1.      Definitions**

| **Affiliate**                                          |   | In                relation to CIMYM or Oncoscience, means any entity or person that                controls, is controlled by, or is under common control with that                Party.                For the purposes of this definition, “control” shall mean direct or                indirect beneficial ownership of 50% (or, outside a Party’s home                territory, such lesser percentage as is the maximum, permitted level                of                foreign investment) or more of the share capital, stock or other                participating interest carrying the right to vote or to distribution                of                profits of that entity or person, as the case may be. |
|--------------------------------------------------------|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                   |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| **Arising                Intellectual Property**       |   | Any                and all of the Arising Patents and the Arising                Know-how.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|                                                   |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| **Arising                Know-how**                    |   | Technical,                commercial and all other information generated by Oncoscienee or                its                Affiliates or sub-licensees during the continuation of this Agreement                that                relates to any of the Licensed Intellectual Property or the Licensed                Product, including any scientific or regulatory data (including clinical                data), product licence applications and approvals, clinical trial                licence                applications and approvals, and development and marketing plans and                activities.                                                                                                                        |
|                                                   |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| **Arising                Patents**                     |   | Any                and all patents and patent applications that may be applied for or                obtained in respect of any invention(s) made by Oncoscience, its                Affiliates or sub-licensees during the continuation of this Agreement                and                which relate to any Licensed Intellectual Property or the Licensed                Product, together with any continuations, continuations in part,                extensions, re-issues, divisions, and any patents, supplementary                protection certificates and similar rights that are based on or derive                priority from the foregoing.                                                                               |
|                                                   |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| **Calendar                Quarter**                    |   | Each                three-month period ending on 31st March, 30th June,                30th September and 3lst December.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|                                                   |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| **Calendar                Year**                       |   | A                year commencing on lst January and ending on 31st                December (but commencing on the Commencement Date in the first year                of                this Agreement and, in the final year of this Agreement, ending on                the                date of the last sale of Licensed Product under this                Agreement).                                                                                                                                                                                                                                                                                                                                                                     |
|                                                   |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| **CIM**                                                |   | The                Center of Molecular Immunology, a scientific research institute based                in                Havana, Cuba.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|                                                   |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| **CIMAB’s                Contract Manufacturer** |   | Any                Person that may from time to time be contracted by CIMAB to manufacture                the Licensed Product, or any component or ingredient thereof, in                accordance with the provisions of this Agreement.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|                                                   |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| **CIMYM                Field and Territory**           |   | (a)                outside the Territory, all fields (including the Field); and (b)                within the Territory, all fields other than the                Field).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |

----

| **Claims**                                                  |   | All                demands, claims and liability (whether criminal or civil, in contract,                tort or otherwise) for losses, damages, legal costs and other expenses                of                any nature whatsoever and all costs and expenses (including without                limitation legal costs) incurred in connection                therewith.                                                                                                                                                                                                                                                                                                                    |
|-------------------------------------------------------------|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                        |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| **Co-exclusive                Licence**                     |   | A                licence whereby:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|                                                        |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|                                                        |   | (a)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | both                CIMAB and Oncoscienee may exercise the licensed rights in the field                and                territory of the licence in question |
|                                                        |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |   |
|                                                        |   | (b)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Oncoscience                may grant sub-licences to the extent permitted under Clause 6.4;                and |
|                                                        |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |   |
|                                                        |   | (c)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | CIMAB                may appoint a single, further licensee from time to time in each                part of                such field and territory to exercise such rights in its place,                but |
|                                                        |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |   |
|                                                        |   | (d)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | except                as described in (c) above CIMAB may not grant further licences in                such                field and territory for as long as the co-exclusive licence continues,                subject to the provisions of this Agreement and the requirements                of any                applicable law. |
|                                                        |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |   |
| **Commencement                Date**                        |   | The                date of execution of this Agreement by the Parties (or, if they sign                on                different dates, the last date of signature of this Agreement by                a                Party).                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|                                                        |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| **Delivered                Items**                          |   | Has                the meaning given in Clause 4.2.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|                                                        |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| **Development                and Commercialisation Plan**   |   | The                development and commercialisation plan for Licensed Product to be                defined                and agreed in accordance with Clause 3.1, as amended from time to                time by                agreement in writing of the Parties. An initial programme of work,                which                is anticipated to form the basis of a more detailed Development and                Commercialisation Plan, is briefly summarised in the attached Schedule                3.                                                                                                                                                                           |
|                                                        |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| **Development                and Commercialisation Report** |   | The                report described in Clause 3.4 as amended from time to                time.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|                                                        |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| **Development                Team Parties**                 |   | CIMYM                and Oncoscience, and “Development Team Party” shall mean either of                them.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|                                                        |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| **Development                Term**                         |   | In                respect of each country in the Territory, means the period from the                Commencement Date until completion of the development of TheraCIM                h-R3 to                the point of first commercial sale of a Licensed Product in that                country                in accordance with the Development and Commercialisation                Plan.                                                                                                                                                                                                                                                                                               |
|                                                        |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| **Diligent                and Reasonable Efforts**          |   | Exerting                such efforts and employing such resources (whether by itself or through                sub-contractors or sub-licensees) as would normally be exerted or                employed                by a reasonable third party pharmaceutical company for a product                of                similar market potential at a similar stage of its product life,                when                utilizing sound and reasonable scientific, business and medical practice                and judgment in order to develop the product in a timely manner and                maximize the economic return to the Parties from its                commercialisation. |

----

| **Field**                                         |   | The                treatment of cancer in humans.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|---------------------------------------------------|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                              |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| **Gross                Sales Value**              |   | Any                and all amounts received (including the value of any non-monetary                consideration received) for the sale of the Licensed Product by                Oncoscience or its Affiliates from a third party (including any of                Oncoscience’s sub-licensees) in an arm’s length transaction exclusively                for money (or where the sale is not at arm’s length, the price that would                have been so invoiced and received if it had been at arm’s length), after                deduction of all documented: |
|                                              |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |   |
|                                              |   | (a)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | normal                trade discounts actually granted and any credits actually given (including                for rejected or returned Licensed Product), |
|                                              |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |   |
|                                              |   | (b)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | rebates                to customers and third parties, |
|                                              |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |   |
|                                              |   | (c)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | provided                the amounts are separately charged on the relevant invoice any costs                of                packaging, insurance, carriage and freight, |
|                                              |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |   |
|                                              |   | (d)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | any                value added tax or other sales or use tax charged to the                customer |
|                                              |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |   |
|                                              |   | (e)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | any                import or export duties or similar applicable government levies;                provided                that such deductions do not exceed reasonable and customary amounts                in the                markets in which such sales occurred; |
|                                              |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |   |
|                                              |   | provided                that in no event the total of deductions referred to in paragraphs                (a) to                (e) above will exceed 10% (ten percent) of the total                invoice.                                                                                                                                                                                                                                                                                                                                                                                  |
|                                              |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |   |
| **Initial                Development Programme**  |   | A                programme of development to be conducted by Oncoscience in accordance                with                the provisions of Schedule 3 Part A.                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|                                              |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| **Joint                Development Team**         |   | A                committee to be established, and operating, in accordance with the                provisions of Clause 2.                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|                                              |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| **Know-how**                                      |   | The                Licensed Know-how and the Arising Know-how.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|                                              |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| **Licensed                Intellectual Property** |   | Any                and all of the Licensed Patent Rights and Licensed Know-how.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|                                              |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| **Licensed                Know-how**              |   | Technical                information in the possession of CIMYM or CIMAB in the Field relating                to                (a) TheraCIM h-R3 and/or (b) the inventions claimed in the Licensed                Patent                Rights, and being further described in the attached Schedule 2, in                each                case to the extent that such information is relevant to the development                and commercialisation of the Licensed                Product.                                                                                                |

----

| **Licensed                Patent Rights** |   | The                patents and patent applications described in the attached Schedule                1                subject to the provisions of Schedule 1, together with any continuations,                continuations in part, extensions, reissues, divisions, and any patents,                supplementary protection certificates and similar rights that are                based on                or derive priority from the foregoing.                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|-------------------------------------------|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                      |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| **Licensed                Product**       |   | TheraCIM                h-R3 that is sold or otherwise supplied by Oncoscience or its Affiliate                or                sub-licensee and which (a) is within any Valid Claim of the Licensed                Patent Rights and/or (b) is the subject of any Orphan Drug Status                in the                Territory; and/or (c) incorporates, or its development makes use                of, any                of the Licensed Know-how.                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|                                      |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| **Major                Country**          |   | Germany,                France, Italy, Spain or the United Kingdom.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|                                      |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| **Milestone                Receipts**     |   | The                amount of any payment, excluding Value Added Tax, (other than sales                income                on which Oncoscience pays CIMYM a royalty under Clause 7.1 or 7.2,                including any payments to Oncoscience or its Affiliate for Licensed                Product supplied directly by Oncoscience or its Affiliate for sale                or                promotion by Oncoscience’s Affiliates or sub-licensees) obtained by, or                due to, Oncoscience or its Affiliate and the value of any non-monetary                receipt, in relation to the development or sub-licensing (including                the                grant of any option over a sub-licence) of any Licensed Intellectual                Property (“Relevant Transaction”), and including any of the following in                relation to a Relevant Transaction: |
|                                      |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|                                      |   | (a)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | up-front,                licence, milestone (whether at the stage of development, marketing                or                otherwise), success, bonus, maintenance and periodic (including annual)                fees and other payments, and minimum royalty payments (to the extent                not                offset against royalties based on sales and coming within the definition                of Royalty Receipts), due under any sub-licence                agreement; |
|                                      |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |   |
|                                      |   | (b)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | any                receipt greater than actual incurred cost in respect of the funding                of                research or development activities related to the Licensed Product,                provided that such incurred costs shall not include any costs that                were                incurred prior to the date of the agreement under which such funding                was                provided; |
|                                      |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |   |
|                                      |   | (c)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | where                any sub-licence is to be granted under cross-licensing arrangements,                the                value of any third party licence obtained under such                arrangements; |
|                                      |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |   |
|                                      |   | (d)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | any                premium paid over the fair market value of shares, options or other                securities in respect of any of the share capital of Oncoscience                or its                Affiliate (such fair market value to be determined on the assumption                that                CIMYM had not granted, nor agreed to grant, any rights to Oncoscience                in                respect of any Licensed Intellectual Property); |
|                                      |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |   |
|                                      |   | (e)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | any                loan, guarantee or other financial benefit made or given other than                on                normal market terms; and |

----

|                                               |   | (f)                                                                                                                                                                                                                                                                                                                                                                                  | any                shares, options or other securities obtained from a third                party. |
|----------------------------------------------------|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------|
|                                               |   |                                                                                                                                                                                                                                                                                                                                                                                 |
| **Net                Sales Value**                 |   | The                Gross Sales Value after deduction of the Supply Price.                                                                                                                                                                                                                                                                                                            |
|                                               |   |                                                                                                                                                                                                                                                                                                                                                                                 |
| **Oncoscience                Field and Territory** |   | In                respect of any activity that is licensed to Oncoscience under this                Agreement, shall mean that the activity must occur both within the                Field                and within the Territory.                                                                                                                                                 |
|                                               |   |                                                                                                                                                                                                                                                                                                                                                                                 |
| **Orphan                Drug Status**              |   | The                grant of “orphan designation” by the European Commission for a medicinal                product pursuant to Regulation (EC) No. 141/2000 of 16 December 1999                or                any similar designation in any part of the Territory.                                                                                                   |
|                                               |   |                                                                                                                                                                                                                                                                                                                                                                                 |
| **Parties**                                        |   | CIMYM,                CIMAB and Oncoscience, and “Party” shall mean any of                them.                                                                                                                                                                                                                                                                          |
|                                               |   |                                                                                                                                                                                                                                                                                                                                                                                 |
| **Person**                                         |   | Includes                any individual, firm, company, corporation or other legal                entity.                                                                                                                                                                                                                                                                             |
|                                               |   |                                                                                                                                                                                                                                                                                                                                                                                 |
| **Patents**                                        |   | Any                and all of the Licensed Patent Rights and the Arising Patents.                                                                                                                                                                                                                                                                                                    |
|                                               |   |                                                                                                                                                                                                                                                                                                                                                                                 |
| **Payment                Cap**                     |   | Has                  the meaning given in Clause 7.1.                                                                                                                                                                                                                                                                                                                                |
|                                               |   |                                                                                                                                                                                                                                                                                                                                                                                 |
| **Providing                Parties**               |   | Any                and all of CIMAB (whether on its own behalf or on behalf of CIM)                and CIMYM                and Providing Party shall mean either of them.                                                                                                                                                                                                           |
|                                               |   |                                                                                                                                                                                                                                                                                                                                                                                 |
| **Regulatory                Application**          |   | Any                and all applications that are necessary and appropriate to obtain                Regulatory Approval including, without limitation, all required documents,                data and information concerning, filed or required to be filed, otherwise                submitted by Oncoscience, its Affiliate or licensee to a Regulatory                Authority. |
|                                               |   |                                                                                                                                                                                                                                                                                                                                                                                 |
| **Regulatory                Approval**             |   | Any                and all approvals, licences, registrations or authorisations of any                Regulatory Authority that are necessary for the manufacture, use,                storage,                import, export, transport, marketing, distribution or sale of the                Licensed                Product in any part of the Territory.                        |
|                                               |   |                                                                                                                                                                                                                                                                                                                                                                                 |
| **Regulatory                Authority**            |   | The                European Medicines Evaluation Agency and other regulatory authorities                in                the Territory.                                                                                                                                                                                                                                             |
|                                               |   |                                                                                                                                                                                                                                                                                                                                                                                 |
| **Supply                Agreement**                |   | Any                agreement between CIMAB and Oncoscience under which CIMAB agrees                to                manufacture and supply Oncoscience with Licensed                Product.                                                                                                                                                                                        |
|                                               |   |                                                                                                                                                                                                                                                                                                                                                                                 |
| **Supply                Price**                    |   | The                commercial supply price for the Licensed Product payable by Oncoscience                to                CIMAB in accordance with Clause                5.2.                                                                                                                                                                                                      |

----

| **Territory**                               |   | Shall                mean the following countries and territories: Austria, Belgium, Denmark,                Finland, France, Germany, Greece, Ireland, Italy, Luxembourg, Portugal,                Spain, Sweden, The Netherlands, United Kingdom, Cyprus, Czech Republic,                Estonia, Hungary, Latvia, Lithuania, Malta, Poland, Slovakia, Slovenia,                Bulgaria, Romania, Turkey, Albania, Andorra, Belarus, Bosnia-Herzegovina,                Croatia, Former Yugoslav Republic of Macedonia, Iceland, Liechtenstein,                Moldova, Monaco, Norway, Russia, San Marino, Serbia and Montenegro,                Switzerland, Ukraine and Vatican City. |
|---------------------------------------------|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                        |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| **TheraCIM                h-R3**            |   | A                humanised antibody to the EGF receptor, known scientifically as h-R3                and                which has been given the product name TheraCIM h-R3.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|                                        |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| **Third                Party Manufacturer** |   | Has                the meaning given in Clause 5.4.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|                                        |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| **Valid                Claim**              |   | A                claim of a patent or patent application that has not expired or been                held                invalid or unenforceable by a court of competent jurisdiction in                a final                and non-appealable judgment.                                                                                                                                                                                                                                                                                                                                                                                                                                |

| **2.** | **Joint                Development Team** |
|--------|-------------------------------------------|

| 2.1 | *Formation*.                Within fifteen (15) days after the Commencement Date, the Development                Team                Parties shall establish a Joint Development Team, by each Development                Team                Party designating its initial members to serve on the Joint Development                Team and notifying the other Development Team Party of its dates                of                availability for the first meeting of the Joint Development Team.                The                purpose of the Joint Development Team shall be to oversee the development                of Licensed Product for purposes of commercialisation in the Oncoscience                Field and Territory. The Joint Development Team shall consist of                not more                than three (3) representatives designated by each Development Team                Party.                Each representative shall have relevant and appropriate expertise                in order                to oversee the development of the Licensed Product. If a representative                of                a Development Team Party is unable to attend a meeting of the Joint                Development Team, such Development Team Party may designate an alternate                to attend such meeting. In addition, each Development Team Party                may, at                its discretion, invite a reasonable number of other employees, consultants                or scientific advisors to attend the meetings of the Joint Development                Team, provided that such invitees are bound by appropriate confidentiality                obligations. Each Development Team Party may change one or all of                its                representatives to the Joint Development Team at any time upon notice                to                the other Development Team Party. |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 2.2 | *Meetings*.                The Joint Development Team shall meet quarterly and at such other                times as                the Parties may agree. The first meeting of the Joint Development                Team                shall be held as soon as reasonably practicable, but in no event                later                than 30 days after the Commencement Date. Meetings shall be held                at such                place or places as are mutually agreed or by teleconference or                videoconference; provided, however, that there shall be at least                one                face-to-face meeting per calendar                year. |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 2.3 | *Responsibilities*.                During the Development Term, the Joint Development Team                shall: |
|-----|------------------------------------------------------------------------------------------------------------------|

|  | (a) | elaborate                the Development Commercialisation Plan in accordance with Clause                3.1 |
|--|-----|--------------------------------------------------------------------------------------------------------------|

|  | (b) | review                and unanimously approve (or, if the members of the Joint Development                Team                are unable to reach unanimous agreement, recommend to the Parties)                the                overall                development strategy for Licensed Product in the Oncoscience Field                and                Territory                (including, without limitation, setting criteria for progression                of                Licensed                Product to the next stage of development under the Development and                Commercialisation                Plan); |
|--|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | (c) | review                and recommend to the Parties modifications to the Development and                Commercialisation Plan (including the resources to be allocated and                the                timelines contained in the Development and Commercialisation                Plan); |
|--|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | (d) | facilitate                the transfer of Know-How between the Parties for purposes of conducting                the Development and Commercialisation                Plan; |
|--|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | (e) | regularly                assess the progress of Oncoscience in its conduct of the Development                and                Commercialisation Plan; and |
|--|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | (f) | perform                such other activities as are contemplated under this Clause 2 and                Clause                1. For the avoidance of doubt the Joint Development Team shall not                have                any role or responsibility in relation to determining whether Oncoscience                has complied or will comply with its obligations to CIMYM under Clauses                3                or 8. |
|--|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 2.4 | *Disputes*.                If agreement cannot be reached within the Joint Development Team,                Oncoscience shall have the right to make the final determination                concerning the resolution of the disagreement. Notwithstanding the                foregoing, in the case of a disagreement involving a material matter,                prior to invoking its rights under this Clause 2.4, Oncoscience agrees                to                have its chief executive contact the chief executive of CIMYM for                the                purpose of discussing the disagreement and attempting to reach a                consensus. It shall be the goal of the chief executives to reach                a                consensus within five (5) days of the date on which contact is initiated                by the chief executive of Oncoscience, it being understood that (i)                in the                event of an extraordinary circumstance requiring a faster resolution                (e.g., a safety issue or extraneous timing issue), Oncoscience shall                have                the right to make the final determination prior to the end of such                five                (5) day period if a consensus has not been achieved by the required                time                for resolution and (ii) in the event that a consensus has not been                achieved within ten (10) days of the date on which contact is initiated                by                the executive officer of Oncoscience, Oncoscience shall have the                right to                make the final determination. For the avoidance of doubt, Oncoscience                shall not have any right, under this clause, to determine whether                it has                complied or will comply with its obligations to CIMYM under Clauses                2.4 or                8. |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| **3.** | **Development                and Commercialisation** |
|--------|------------------------------------------------------|

| 3.1 | *Development                and Commercialisation Plan.* |
|-----|----------------------------------------------------------|

| 3.1.1 | Within                90 days of the Commencement Date, the Joint Development Team shall                prepare                a written plan (“Development and Commercialisation Plan”) that expands                upon the initial development plan set out in Schedule 3 and will                describe,                and provide a timeline for: |
|-------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|  | (a) | all                development activities for the Licensed Product in the Oncoscience                Field                and Territory, addressing each phase of development and the budget                for                completion of such activities, and providing detailed information                on the                activities to be conducted in the next 12 month                period; |
|--|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | (b) | intellectual                property protection strategy, including applying for Orphan Drug                Status,                patents and supplementary protection                certificates |
|--|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | (c) | sub-licensing                strategy; |
|--|-----|----------------------------------------|

|  | (d) | clinical                and registration strategy, with a view to expediting regulatory approval                for Licensed Product; and |
|--|-----|-------------------------------------------------------------------------------------------------------------------------------------------|

|  | (e) | commercialisation                strategy. |
|--|-----|--------------------------------------------|

| 3.1.2 | The                Joint Development Team shall update the Development and Commercialisation                Plan on a regular basis (and at least                annually). |
|-------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.2 | *Development                and commercialisation activities*.                Oncoscience shall be responsible for the development and commercialisation                (in accordance with the Development and Commercialisation Plan) of                the                Licensed Product in the Oncoscience Field and Territory. Such development                and commercialisation shall be carried out under the oversight and                management of the Joint Development Team and in accordance with the                provisions of this Agreement. |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.3 | *Development                and commercialisation costs*.                Oncoscience shall bear all costs associated with the development                and                commercialisation of Licensed Product in the Oncoscience Field and                Territory, including costs incurred in the Development and                Commercialisation Plan. If any Providing Party agrees with Oncoscience                to                conduct work as part of the Development and Commercialisation Plan                (which                may include advice given to the Joint Development Team), the Providing                Party’s costs of conducting such work shall be borne by Oncoscience, with                the time costs of the Providing Party’s representatives being charged to                Oncoscience on a daily rate basis. The Providing Party’s daily rate for                its representatives in the work referred to in the previous sentence                shall                be agreed between the Parties or, if they are unable to agree, the                rate                shall be US$ 1,000 (one thousand US dollars) per day plus any                product-related consumable costs and external costs associated with                such                work. |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.4 | *Reporting*.                Without prejudice to the generality of Oncoscience’s obligations under                Clauses 8.1 and 9.2, Oncoscience shall provide a report (“Development and                Commercialisation Report”) to CIMYM at least annually to CIMYM. In                addition, Oncoscience shall provide to CIMYM a quarterly, written                status                update on all clinical, development and commercial activities being                undertaken, and from time to time upon request, showing all past,                current                and projected activities taken or to be taken by Oncoscience to bring                Licensed Product to market and maximise the sale of Licensed Product                in                the Oncoscience Field and Territory, and including details of all                Arising                Intellectual Property. CIMYM’s receipt or approval of any such report                shall not be taken to waive or qualify Oncoscience’s obligations under                Clause 8.1. |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.5 | *Exchange                of data*.                It is CIMYM’s or CIMAB’s intention to grant licences to commercialise                TheraCIM h-R3 in the CIMYM Field and Territory. Accordingly, each                of the                Parties or its licensee(s), may generate data in relation to Licensed                Products that is useful to the other Parties in connection with their                commercialisation of Licensed Products. To facilitate such                commercialisation, Oncoscience shall disclose and provide to CIMYM                and                CIMAB all Arising Intellectual Property in accordance with the provisions                of Clause 3.4. CIMYM (or CIMAB as applicable) and Oncoscience shall                use                reasonable efforts to reach agreement with CIMYM’s (or CIMAB’s as                applicable) other licensee(s) of TheraCIM h-R3 for the disclosure                to                Oncoscience of clinical data in respect of TheraCIM h-R3 that is                generated                by such licensee(s). |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| **4.** | **Know-how                and Confidential                Information** |
|--------|-------------------------------------------------------------------------|

| 4.1 | *Provision                of Know-how*.                Upon Oncoscience’s reasonable request, CIMYM shall supply Oncoscience with                all Licensed Know-how in its possession that is specifically relevant                to                the development and commercialisation of TheraCIM h-R3 and that CIMYM                is                at liberty to disclose and has not previously been disclosed and                which is                reasonable necessary to enable Oncoscience to undertake the further                development of Licensed Product. The Licensed Know-how shall be subject                to                the confidentiality provisions of Clause 4.4. The method of any such                supply shall be as specified in Schedule 2 but shall not require                CIMYM to                undertake more than 5 man-days of work, unless otherwise agreed in                writing                between the Parties. |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 4.2 | *Status                of Know-how*.                Oncoscience acknowledges that the Licensed Know-how is subject to                further                development. Accordingly, specific results cannot be guaranteed and                any                results, materials, information or other items, including the Licensed                Know-how and inventions claimed in the Licensed Patent Rights (together                “Delivered Items”) provided under this Agreement are provided “as is” and                without any express or implied warranties, representations or                undertakings. As examples, but without limiting the foregoing, CIMYM                does                not give any warranty that Delivered Items are of merchantable or                satisfactory quality, are fit for any particular purpose, comply                with any                sample or description, or are viable, uncontaminated, safe or                non-toxic. |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 4.3 | *Use                of Know-how*.                Oncoscience undertakes that for a period of 10 years from the date                of                first commercial sale of Licensed Product in the Territory or for                so long                as any substantial part of the Know-how remains subject to the obligations                of confidence of Clause 4.4, whichever is the shorter, it will not                use the                Licensed Know-how for any purpose except as expressly licensed hereby                and                in accordance with the provisions of this                Agreement. |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 4.4 | *Confidentiality                obligations*.                Each Party (“Receiving Party”)                undertakes: |
|-----|------------------------------------------------------------------------------------------------------------------------------------|

|  | (a) | to                maintain as secret and confidential all Know-how and other technical                or                commercial information obtained directly or indirectly from the other                Party (“Disclosing Party”) in the course of or in anticipation of this                Agreement and to respect the Disclosing Party’s rights                therein, |
|--|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | (b) | to                use the same exclusively for the purposes of this Agreement,                and |
|--|-----|---------------------------------------------------------------------------------------------------|

|  | (c) | to                disclose the same only to those of its employees, contractors and                sub-licensees pursuant to this Agreement (if any) to whom and to                the                extent that such disclosure is reasonably necessary for the purposes                of                this Agreement. |
|--|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 4.5 | *Exceptions                to obligations*.                The provisions of Clause 4.4 shall not apply to Know-how and other                information which the Receiving Party can demonstrate by reasonable,                written evidence: |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | (a) | was,                prior to its receipt by the Receiving Party from the Disclosing Party,                in                the possession of the Receiving Party and at its free disposal;                or |
|--|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | (b) | is                subsequently disclosed to the Receiving Party without any obligations                of                confidence by a third party who has not derived it directly or indirectly                from the Disclosing Party; or |
|--|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | (c) | is                or becomes generally available to the public through no act or default                of                the Receiving Party or its agents, employees, Affiliates or                sub-Licensees. |
|--|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 4.6 | *Disclosure                to court, etc*.                If the Receiving Party is required to disclose confidential information                to                the courts of any competent jurisdiction, or to any government regulatory                agency or financial authority, such disclosure shall not be a breach                of                Clause 4.4, provided that the Receiving Party shall (i) inform the                Disclosing Party as soon as is reasonably practicable, and (ii) at                the                Disclosing Party’s request seek to persuade the court, agency or authority                to have the information treated in a confidential manner, where this                is                possible under the court, agency or authority’s                procedures. |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 4.7 | *Disclosure                to employees*. The Receiving Party shall procure that all of its                employees, contractors, consultants, advisers and sub-licensees pursuant                to this Agreement (if any) who have access to any of the Disclosing                Party’s information to which Clause 4.4 applies, shall be made aware of                and subject to these obligations and shall have entered into written                undertakings of confidentiality at least as restrictive as Clauses                4.4 and                4.5 and which apply to the Disclosing Party’s                information. |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| **5.** | **Manufacturing                and supply** |
|--------|---------------------------------------------|

| 5.1 | *Clinical                supply*.                CIMAB shall supply to Oncoscience, and Oncoscience shall purchase                from                CIMAB, for its own use and that of its Affiliates and sub-licensees,                in                finished form with one hundred percent (100%) of Oncoscience’ s                requirements of TheraCIM h-R3 and Licensed Product for all clinical                development purposes. Such clinical requirements shall be supplied                to                Oncoscience: |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | (a) | In                respect of Oncoscience’s requirements for clinical trials for the purposes                of seeking Regulatory Approvals in the Field in the Territory, at                a supply                price of US$ 500 (five hundred US dollars) per gram. Payment will                be made                50% in advance for each instalment of product that is ordered under                this                paragraph (a) when it is available for delivery. The second half                of                payment will be paid within 30 days after receiving the                product. |
|--|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | (b) | For                all other supply for clinical purposes (including without limitation                supply for Phase IV studies and for studies that are not required                for                obtaining Regulatory Approvals), a supply price equal to US$1,100                (one                thousand one hundred US dollars) per                gram. |
|--|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 5.2 | *Commercial                Supply*. |
|-----|-------------------------------------|

| 5.2.1 | CIMAB                shall supply to Oncoscience, and Oncoscience shall purchase from                CIMAB, as                active pharmaceutical ingredient, or if the Parties mutually agree                at the                time of entering into the supply agreement described in Clause 5.5, in                finished form with one hundred percent (100%) of Oncoscience’s                requirements of Licensed Products for all commercial purposes. CIMAB                may                elect to have such requirements supplied to Oncoscience by one or                more of                CIMAB’s Contract Manufacturer(s). In such case, the supply agreement to                be                entered into shall be concluded nonetheless between Oncoscience and                CIMAB                and not between Oncoscience and CIMAB’s Contract Manufacturer(s).                Oncoscience’s quantity requirements shall include those of its Affiliates                and sub-licensees. The supply price for the Licensed Product payable                by                Oncoscience or its Affiliates to CIMAB (the “**Supply                Price**”)                shall be: |
|-------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | (a) | In                the case of sales of the Licensed Product made directly by Oncoscience                or                its Affiliates to a third party other than to its sub-licensees (i)                until                the Payment Cap is reached, US$ 1,250 (one thousand two hundred and                fifty                US dollars) per gram of Licensed Product and (ii) after the Payment                Cap is                reached, as mutually agreed to between the Parties, acting reasonably;                and |
|--|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | (b) | In                the case of sales of the Licensed Product made by Oncoscience or                its                Affiliates to its sub-licensee(s), US$ 1,250 (one thousand two hundred                and                fifty US dollars) per gram of Licensed                Product. |
|--|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 5.3 | *Specifications*.                CIMAB undertakes that all Licensed Product supplied to Oncoscience                will be                manufactured in accordance with mutually agreed upon specifications                (inclusive of specifications in an approved Marketing Authorization                and                Good Manufacturing Practices of the EMEA the relevant regulatory                authorities in the other countries in the Territory, and the relevant                regulatory authorities in the countries of manufacture of the Licensed                Product, and will not be adulterated or misbranded under applicable                laws,                regulations or guidelines, and that the manufacturer will have in                force                all necessary Regulatory Approvals for the manufacture of Licensed                Product                in accordance with such specifications for the purposes of supply                and use                of Licensed Product in all countries of the Territory and will be                in good                standing with all Regulatory                Authorities. |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 5.4 | *Right                to Have Manufactured in Event of Default by                CIMAB.* |
|-----|------------------------------------------------------------------------------------------|

| 5.4.1 | In                the event that CIMAB or CIMAB’s Contract Manufacturer is unwilling or                unable to manufacture to the specifications required by the relevant                Regulatory Authority or by the terms of any relevant Regulatory Approval,                Oncoscience shall have the right to have manufactured by a Third                Party                Manufacturer (as defined below) one hundred percent (100%) of its                own                clinical and commercial requirements of Licensed Product, in accordance                with the provisions of Clause 5.4.2. In the event that CIMAB is unable                to                supply Oncoscience with its quantity requirements of Licensed Product                (as                described in Clause 5.1 to 5.3) for a period of one or more Calendar                Quarters in any given two year period Oncoscience shall have the                right to                have manufactured by a Third Party Manufacturer as defined below                its own                clinical and commercial requirements of Licensed Product, in accordance                with the provisions of Clause 5.4.2, but Oncoscience shall continue                to                purchase at least 50% of its quantity requirements from CIMAB or                CIMAB’s                Contract Manufacturer for as long as it is willing and able to do                so. |
|-------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 5.4.2 | To                enable Oncoscience to have Licensed Product manufactured for it in                accordance with Clause 5.4.1, the Parties shall, at the request of                Oncoscience, make arrangements for the transfer of relevant CIMAB                manufacturing technology and know-how to a manufacturer nominated                by                Oncoscience (“Third Party Manufacturer”). CIMAB shall supply such                technology and know-how free of charge but without any obligation                to bear                any of Oncoscience’s costs. Prior to the transfer of such manufacturing                technology and know-how, the Third Party Manufacturer shall be required                to                enter into an agreement with CIMAB, on terms satisfactory to CIMAB,                under                which the Third Party Manufacturer shall undertake to keep CIMAB’s                manufacturing technology and know-how confidential and to use it                only for                the supply of Licensed Product to Oncoscience or its Affiliate or                sub-licensee and only in circumstances where Clause 5.4.1 applies.                The                terms of such agreement between CIMAB and a Third Party Manufacturer                shall                be deemed satisfactory to CIMAB if the terms are identical to the                terms of                an equivalent agreement between CIMAB and CIMAB’s Contract                Manufacturer. |
|-------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 5.5 | *Supply                Agreement*. Licensed Product supplied by CIMAB or CIMAB’s Contract                Manufacturer(s) to Oncoscience for clinical and commercial purposes                shall                be supplied to Oncoscience pursuant to the terms of a separate Supply                Agreement. Oncoscience and CIMAB shall use good faith efforts to                negotiate                and enter into such a supply agreement at least six (6) months prior                to                the submission of a Regulatory Application for such Licensed Product                in                the Territory. In addition to more detailed terms regarding form                of                product, supply price, specifications, shortage of supply and default                manufacturing rights as are specified in this Clause 5, each Supply                Agreement shall contain forecast procedures, permitted variances                from                forecasted amounts, order and delivery times, quality control and                quality                assurance procedures, audits, yield ratios, maintenance of inventory,                procedures and remedies for rejection of non-conforming product,                record                retention, compliance with laws, and other customary provisions.                The terms                of the Supply Agreement shall be consistent with the provisions of                this                Clause 5, unless otherwise agreed in writing by CIMAB and                Oncoscience. |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| **6.** | **Grant                of rights** |
|--------|------------------------------------|

| 6.1 | *Licensed                Intellectual Property.* |
|-----|--------------------------------------------------|

| 6.1.1 | CIMYM                hereby grants to Oncoscience, subject to the provisions of this                Agreement: |
|-------|----------------------------------------------------------------------------------------------------------------|

|  | (a) | an                exclusive licence in the Oncoscience Field and Territory (except                that in                Russia, Belarus and Ukraine it shall be Co-exclusive Licence in the                Field)                under the Licensed Patent Rights, with the right to sub-license,                subject                to Clause 6.4 below, to develop, use and sell Licensed Product but                only in                the Oncoscience Field and Territory;                and |
|--|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | (b) | an                exclusive licence in the Oncoscience Field and Territory (except                that in                Russia, Belarus and Ukraine it shall be Co-exclusive Licence in the                Field)                to use the Licensed Know-how, with the right to sub-license, subject                to                Clause 6.4 below, to develop, use and sell Licensed Product but only                in                the Oncoscience Field and Territory;                and |
|--|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | (c) | an                exclusive licence in the Oncoscience Field and Territory (except                that in                Russia, Belarus and Ukraine it shall be Co-exclusive Licence in the                Field)                to have Licensed Product manufactured for it by a Third Party                Manufacturer, but only in the circumstances described in Clause                5.4. |
|--|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 6.1.2 | In                the event that CIMAB wishes to exercise its Co-exclusive rights in                Russia,                Belarus or Ukraine, it shall notify Oncoscience of its intended activities                in such countries, in particular to ensure that Oncoscience’s rights under                this Agreement are not adversely                affected. |
|-------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 6.2 | *Arising                Intellectual Property (including clinical                data).* |
|-----|------------------------------------------------------------------------------------------|

| 6.2.1 | Arising                Intellectual Property shall be owned by the Party (which for the                purposes                of this clause may include CIM) that invents or creates it, and if                it is                jointly invented or created by two or more of the Parties it shall                be                owned jointly by those Parties in equal, undivided shares, subject                to the                provisions of this Agreement including the following                provisions: |
|-------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | (a) | Recognising                the contribution that CIM’s scientists have made, and are continuing to                make, to the development of TheraCIM h-R3 and the current stage of                its                development, the Parties anticipate that, as a matter of law, CIM                scientists should be named as inventor(s) or joint inventor(s) of                any new                inventions made under this Agreement. Accordingly, unless the Party                filing                a patent application in respect of Arising Intellectual Property                is                advised by external patent counsel that such naming would prejudice                the                validity of the resulting Arising Patents, all Arising Patents shall                be                considered to have been jointly invented by representatives of CIM                and                Oncoscience, and accordingly shall be jointly owned by them in equal,                undivided shares, subject to the provisions of this                Agreement; |
|--|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | (b) | It                is anticipated that Arising Know-how will be generated by clinicians                and                other Persons in the course of, or arising from, clinical studies                that                have been designed by the Joint Development Team. Accordingly, it                is                agreed that all Arising know-how developed in, or arising from, the                work                performed under the Development and Commercialisation Plan shall                be                jointly owned by CIM and Oncoscience in equal, undivided shares,                subject                to the provisions of this Agreement;                and |
|--|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | (c) | Subject                to paragraphs (a) and (b) above, where Arising Intellectual Property                consists of an improvement to, or a new application of, Licensed                Intellectual Property and, as a matter of law, is made solely by                employees                of Oncoscience, it shall be owned solely by                Oncoscience. |
|--|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 6.2.2 | CIMAB                hereby grants and agrees to grant to Oncoscience an exclusive, fully                paid-up and royalty-free licence under Arising Intellectual Property                in                the Oncoscience Field and Territory, with the right to sub-license,                to                research, develop, make, have made, import, use, sell and otherwise                deal                in any and all products and processes in the Oncoscience Field and                Territory. |
|-------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 6.2.3 | Oncoscience                hereby grants and agrees to grant to CIMYM and CIMAB an exclusive,                fully                paid-up and royalty-free licence under Arising Intellectual Property                in                the CIMYM Field and Territory, with the right to sub-license, to                research,                develop, make, have made, import, use, sell and otherwise deal in                any and                all products and processes in the CIMYM Field and                Territory. |
|-------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 6.3 | *Formal                licences*. If requested by Oncoscience, and at Oncoscience’s                administrative cost, the Parties shall execute such formal licences                as may                be necessary or appropriate for registration with Patent Offices                and other                relevant authorities in the Territory. In the event of any conflict                in                meaning between any such licence and the provisions of this Agreement,                the                provisions of this Agreement shall prevail. The Parties shall use                reasonable endeavours to ensure that, to the extent permitted by                relevant                authorities, this Agreement shall not form part of any public                record. |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 6.4 | *Sub-licensing*.                Oncoscience shall be entitled to grant sub-licences (which for the                purposes of this clause shall include any option or right to acquire                a                sub-licence) of its rights under this Agreement to any person (including                without limitation any Affiliate of Oncoscience), provided                that: |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | (a) | Oncoscience                shall first provide written notice to CIMYM of any request to enter                into a                sub-license and shall provide with such notice a copy of the proposed                sub-license agreement. CIMYM shall provide its response to any such                request within thirty (30) days of its receipt of Oncoscience’s notice,                failing which, it shall be deemed to have consented to such request.                CIMYM                shall have no reason to withhold its consent to such request provided                that                the proposed sub-license agreement complies with the terms of this                Clause                6.4. Oncoscience shall provide to the Parties, within thirty (30)                days of                its execution, a fully executed copy of the sub-license                agreement; |
|--|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | (b) | the                scope of the sub-licence shall not exceed the scope of the licence                granted                under this Agreement and, in particular, shall not include any                manufacturing rights; |
|--|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | (c) | the                sub-licence shall include obligations on the sub-licensee which are                equivalent to the obligations on Oncoscience under this Agreement                (and the                sub-licensee shall not have any right to grant sub-sub-licences without                CIMYM’s prior written agreement, which consent may be withheld at CIMYM’s                sole discretion); |
|--|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | (d) | if                agreed between CIMYM and the sub-licensee, the sub-licence shall                continue                in force as an agreement between CIMYM (in place of Oncoscience)                and the                sub-licensee or, if no such agreement is made, the sub-licence shall                terminate automatically on the termination of this Agreement for                any                reason; |
|--|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | (e) | clinical                trials in the territory of the sub-licensee shall commence not later                than                18 months from the date of the conclusion of the sub-licence agreement,                failing which the sub-licence shall automatically                terminate; |
|--|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | (f) | Oncoscience                shall have no ownership interest of any kind in the proposed sub-licensee;                and |
|--|-----|--------------------------------------------------------------------------------------------------------------------------|

|  | (g) | Oncoscience                shall be responsible for any breach of the sub-licence by the                sub-licensee, as if the breach had been that of Oneoscience under                this                Agreement, and Oncoscience shall indemnify CIMYM against any loss,                damages, costs, claims or expenses which are awarded against or suffered                by CIMYM as a result of any such breach by the                sub-licensee. |
|--|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 6.5 | *Reservation                of rights within Field and Territory*.                For the avoidance of doubt, CIMYM reserves                the right for itself and its licensees and assigns to use TheraCIM                h-R3                and the Licensed Intellectual Property in the Oncoscience Field and                Territory with the prior consent of Oncoscience (a) for the purposes                of                research; and/or (b) for the purposes of development (including clinical                trials) of products with a view to obtaining regulatory approval                for such                products in the CIMYM Field and Territory. If CIMYM wishes to conduct                research or development activities in the Oncoscience Field and Territory                in accordance with the provisions of this clause, it will so inform                Oncoscience and give Oncoscience a first opportunity to propose terms                for                an agreement with CIMYM under which Oncoscience would assist CIMYM                with                such activities at the cost of CIMYM. It is understood and agreed                that                CIMYM will be required under regulatory GCP to retain archive samples                of                materials. |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 6.6 | *No                other licence*.                It is acknowledged and agreed that no licence is granted by CIMYM                to                Oncoscience other than the licence(s) expressly granted by the provisions                of this Clause 6. Without prejudice to the generality of the foregoing                CIMYM reserves all rights under the Licensed Intellectual Property                in the                CIMYM Field and Territory. |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 6.7 | *Quality*.                Oncoscience shall ensure that all Licensed Product marketed by it                and its                sub-licensees is of satisfactory quality and complies with all applicable                laws and regulations in each part of the                Territory. |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 6.8 | *Acknowledgment                by CIMAB*.                CIMAB acknowledges and agrees that CIMYM has been granted the necessary                rights and licences to enable it to grant the licences referred to                in                Clauses 6.1. and 6.4 of this                Agreement. |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 6.9 | *Acknowledgment                by CIMYM and CIMAB*.                CIMYM and CIMAB acknowledge and agree that, subject to Clause 6.4(g),                Oncoscience is free to organize its distribution of the Licensed                Product                and determine its sales price of the Licensed Product within the                Oncoscience Field and Territory at its own discretion. Oncoscience                is also                free to determine its sales price vis-à-vis its sub-licensees. However,                only for the purpose of calculating the royalties pursuant to Article                7 of                this Agreement the supply price charged by Oncoscience to its                sub-licensees shall be deemed $ 2,312.50 (two thousand three hundred                and                twelve US dollars and fifty cents) per gram if and as far as Oncoscience                charges a supply price to its sub-licensees which is below the threshold                of $ 2,312.50 (two thousand three hundred and twelve US dollars and                fifty                cents) per gram. |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| **7.** | **Payments** |
|--------|--------------|

| 7.1 | *Payments                prior to reaching Payment Cap*.                Until such time as the total amount of payments made by Oncoscience                to                CIMYM under this Clause 7.1 reaches US$[*] ([*] US dollars) (excluding                VAT                or other taxes or charges and excluding the amount of any payments                from                Oncoscience to CIMYM in respect of the supply of products, materials                or                services) (the “Payment Cap”), Oncoscience shall pay to CIMYM the                following amounts: |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | (a) | [*]%                ([*] percent) of all Milestone Receipts, which shall be payable within                30                (thirty) days of any such Milestone Receipt being received by Oncoscience                or its Affiliate; |
|--|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | (b) | In                the case of sales of the Licensed Product made directly by Oncoscience                or                its Affiliates to a third party other than its                sub-licensee(s): |
|--|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | (i) | a                royalty of [*]% ([*] percent) of Net Sales Value of all Licensed                Product;                and |
|--|-----|------------------------------------------------------------------------------------------------------------------------------|

|  | (ii) | an                additional royalty of US$ [*] ([*] US dollars) per gram of the                Licensed Product; and |
|--|------|----------------------------------------------------------------------------------------------------------------------------|

----

|  | (c) | In                the case of sales of the Licensed Product made by Oncoscience or                its                Affiliates to its sub-licensee(s), a royalty of [*]% of Net Sales                Value of                all Licensed Product. |
|--|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.2 | *Payments                after reaching Payment Cap.* |
|-----|-------------------------------------------------------|

| 7.2.1 | *Royalties*.                After the total amount of payments made by Oncoscience to CIMYM under                Clause 7.1 has reached the Payment Cap, Oncoscience shall pay to                CIMYM the                following amounts: |
|-------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | (a) | [*]%                ([*] percent) of all Milestone Receipts, which shall be payable                within 30 (thirty) days of any such Milestone Receipt being received                by Oncoscience or its Affiliates; |
|--|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | (b) | In                the case of sales of the Licensed Product made directly by Oncoscience                or                its Affiliates to a third party other than its sub-licensee(s), a                royalty                on cumulative Gross Sales Value of Licensed Product in each Calendar                Year,                at the following incremental rates: |
|--|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ***Incremental                Gross Sales Value in Calendar Year***                |   | ***Royalty                rate*** |   |
|------------------------------------------------------------------------------------|--------|-----------------------------------|--------|
| Less                than or equal to US$[*]                                        |   |                              | [*]    | % |
| Greater                than US$[*] and less                than or equal to US$[*] |   |                              | [*]    | % |
| Greater                than US$[*] and less                than or equal to US$[*] |   |                              | [*]    | % |
| Greater                than US$[*]                                                 |   |                              | [*]    | % |

*Example*

| (i)   |   | [*]%              on the first US$175M of Gross Sales Value =   |   |   | US$[*] |    |
|-------|--------|-----------------------------------------------------------------|--------|--------|--------|---------|
| (ii)  |   | [*]%              on the next US$175M of Gross Sales Value =    |   |   | US$[*] |    |
| (iii) |   | [*]%              on the remaining US$20M of Gross Sales Value= |   |   | US$[*] |    |
| (iv)  |   | Total              amount of royalty due in Calendar Year =     |   |   | US$[*] | ;  |

|  | (c) | In                the case of sales of the Licensed Product made by Oncoscience or                its                Affiliates to                its sub-licensee(s), a royalty of [*]% of Net Sales Value of all                Licensed                Product. |
|--|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.3 | *Payment                dates*. Royalties due under this Agreement shall be paid within 90                days of the end of each Calendar Quarter, in respect of sales of                Licensed                Product made during such Calendar Quarter, and within 120 days of                the                termination of this Agreement. |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.4 | *Payment                terms*. All sums due under this                Agreement: |
|-----|-----------------------------------------------------------------------------------|

|  | (a) | are                exclusive of Value Added Tax which where applicable will be paid                by                Oncoscience to CIMYM in addition; |
|--|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | (b) | shall                be paid in US dollars (or such other currency as the Parties may                agree)                and, in the case of sales or sub-license income received by Oncoscience                in                a currency other than US dollars, the income shall be calculated                in the                other currency and then converted into equivalent US dollars at the                purchasing rate for US dollars as quoted by Kreissparkasse Sűdholstein,                Friedrich-Ebert-Damm 38-40 25431 Pinneberg in Germany as at the close                of                business on the last business day of the quarterly period with respect                to                which the payment is made; |
|--|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|  | (c) | shall                be made without deduction of income tax or other taxes charges or                duties                that may be imposed, except insofar as Oncoscience is required to                deduct                the same to comply with applicable laws. The Parties shall cooperate                and                take all steps reasonably and lawfully available to them to avoid                deducting such taxes and to obtain double taxation relief. If Oncoscience                is required to make any such deduction it shall provide CIMYM with                such                certificates or other documents as it can reasonably obtain to enable                CIMYM to obtain appropriate relief from double taxation of the payment                in                question; and |
|--|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | (d) | shall                be made by the due date, failing which CIMYM may charge interest                on any                outstanding amount on a daily basis at a rate equivalent to 3% above                the                US prime lending rate then in                force. |
|--|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.5 | *Exchange                controls, etc*.                If at any time during the continuation of this Agreement Oncoscience                is                prohibited from making any of the payments required hereunder by                a                governmental authority in any country then Oncoscience will within                the                prescribed period for making the said payments in the appropriate                manner                use its best endeavours to secure from the proper authority in the                relevant country permission to make the said payments and will make                them                within 7 days of receiving such permission. If such permission is                not                received within 30 (thirty) days of Oncoscience making a request                for such                permission then, at the option of CIMYM, Oncoscience shall deposit                the                royalty payments due in the currency of the relevant country either                in a                bank account designated by CIMYM within such country or such royalty                payments shall be made to an associated company of CIMYM designated                by                CIMYM and having offices in the relevant country designated by                CIMYM. |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.6 | *Royalty                statements*.                Oncoscience shall send to CIMYM at the same time as each royalty                payment                is made in accordance with Clause 7.3 a statement setting out, in                respect                of each country in which Licensed Product is sold, the types of Licensed                Product sold, the quantity of each type sold, and the total Gross                Sales                Value and Net Sales Value, in respect of each type, expressed both                in                local currency and US dollars and showing the conversion rates used,                during the period to which the royalty payment                relates. |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.7 | *Records* |
|-----|-----------|

| 7.7.1 | Oncoscience                shall keep at its normal place of business detailed and up to date                records                and accounts showing the quantity, description and Gross Sales Value                of                Licensed Product, all the documents corresponding to the deductions,                and                the amount of Milestone Receipts received by it in respect of Licensed                Product, on a country by country basis, and being sufficient to ascertain                the payments due under this                Agreement. |
|-------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.7.2 | Oncoscience                shall make such records and accounts available, on reasonable notice,                for                inspection during business hours by an independent chartered accountant                nominated by CIMYM for the purpose of verifying the accuracy of any                statement or report given by Oncoscience to CIMYM under Clause 7.6.                The                accountant shall be required to keep confidential all information                learnt                during any such inspection, and to disclose to CIMYM only such details                as                may be necessary to report on the accuracy of Oncoscience’s statement or                report. CIMYM shall be responsible for the accountant’s charges unless the                accountant certifies that there is an inaccuracy of more than 5%                (five                percent) in any royalty statement, in which case Oncoscience shall                pay his                charges in respect of that inspection. If the inspection shows that                Oncoscience owes a payment to CIMYM under this Agreement, Oncoscience                shall promptly make such                payment. |
|-------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 7.7.3 | Oncoscience                shall ensure that CIMYM has the same rights as those set out in this                Clause 7.7 in respect of any Affiliate or sub-licensee of Oncoscience                that                is sub-licensed under Licensed Intellectual Property pursuant to                this                Agreement. |
|-------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| **8.** | **Diligence** |
|--------|---------------|

| 8.1 | Oncoscience                shall use Diligent and Reasonable Efforts to develop and commercially                exploit Licensed Product to the maximum extent throughout the Territory.                Without limiting Oncoscience’s obligations under the previous sentence of                this Clause 8.1, Oncoscience shall develop and commercially exploit                Licensed Product in accordance with the Development and Commercialisation                Plan. |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 8.2 | If                CIMYM considers at any time during the period of this Agreement that                Oncoscience has without legitimate reason failed to comply with its                obligations under Clause 8.1, CIMYM shall be entitled to refer to                an                independent expert the following                questions: |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | (a) | whether                Oncoscience has complied with such obligations; and if                not |
|--|-----|--------------------------------------------------------------------------------------------------|

|  | (b) | what                specific action Oncoscience should have taken (“Specific                Action”) in order to have so                complied. |
|--|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 8.3 | The                independent expert shall be appointed in accordance with the provisions                of                Schedule 4 and his decision shall be final and binding on the                Parties. |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 8.4 | If                the expert determines that Oncoscience has failed to comply with                its                obligations under this Clause 8, and if Oncoscience fails to take                the                Specific Action within 6 months of the expert giving his decision                in                accordance with Schedule 4, CIMYM shall be entitled, by giving, at                any                time within 3 months after the end of that 6 month period, not less                than 3                months’ notice to terminate this Agreement and the licences granted to                Oncoscience under Clause 6. |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| **9.** | **Intellectual                property** |
|--------|------------------------------------------|

| 9.1 | *Obtain                and maintain the Licensed Patent Rights*. CIMYM shall, at its cost and                expense: |
|-----|-----------------------------------------------------------------------------------------------------------------------|

|  | (a) | Diligently                seek to obtain valid patents in the name of CIM pursuant to each                of the                patent applications listed in Schedule 1;                and |
|--|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | (b) | pay                all renewal fees in respect of the Licensed Patent Rights as and                when due; |
|--|-----|--------------------------------------------------------------------------------------------------------------|

| 9.2 | *Obtain                and maintain the Arising Patents*. The Parties shall consult with one                another in relation to the filing and maintenance of any Arising                Patents                in respect of any inventions made by Oncoscience, its Affiliates                or                sub-licensees that relate to any of the Licensed Intellectual Property                or                the Licensed Product (“Arising Inventions”). Oncoscience shall or shall                ensure that its Affiliate or sub-licensee shall, at its own cost                and                expense: |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|  | (a) | Diligently                seek to obtain valid patents (in the name of the relevant Parties                as                specified in Clause 6.2.1) in respect of any Arising Inventions;                and |
|--|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | (b) | pay                all renewal fees in respect of the Arising Patents as and when due; |
|--|-----|----------------------------------------------------------------------------------------|

| 9.3 | *Infringement                of the Patents* |
|-----|----------------------------------------------|

| 9.3.1 | Each                Party shall inform the other Party promptly if it becomes aware of                any                infringement or potential infringement of any of the Patents in the                Oncoscience Field and Territory, and the Parties shall consult with                each                other to decide the best way to respond to such                infringement. |
|-------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 9.3.2 | Oncoscience                shall be responsible, at its discretion, for taking action against                infringers of the Licensed Patents in the Oncoscience Field and Territory                at its sole expense, and it shall be entitled to retain any damages                or                other payments or benefits obtained by such action in the Oncoscience                Field and Territory, after reimbursing CIMYM and CIMAB for any reasonable                expenses incurred in assisting it in such action. If Oncoscience                declines                to take action, then CIMYM shall be entitled to take action against                the                third party at CIMYM’s sole expense and CIMYM shall be entitled to all                damages or other sums received from such action, after reimbursing                Oncoscience for any reasonable expenses incurred in assisting it                in such                action. If the alleged infringement is both within and outside the                Oncoscience Field and Territory, the Parties shall also co-operate                with                CIMYM’s and CIMAB’s other licensees (if any) in relation to any such                action and shall divide the costs of such action proportionately                among                Oncoscience and CIMYM’s and CIMAB’s other licensees who participate in                such action. The apportionment of costs between licensees shall be                decided                by CIMYM, acting reasonably. |
|-------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 9.4 | *Infringement                of third party rights* |
|-----|-----------------------------------------------------|

| 9.4.1 | If                any warning letter or other notice of infringement is received by                a Party,                or legal suit or other action is brought against a Party, alleging                infringement of third party rights in the manufacture, use or sale                of the                Licensed Product or use of any Patents, that Party shall promptly                provide                full details to the other Party, and the Parties shall discuss the                best                way to respond. |
|-------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 9.4.2 | CIMYM                shall have the right but not the obligation to defend such suit and                shall                have the right to settle with such third party, provided that if                any                action or proposed settlement involves the making of any statement,                express or implied, concerning the validity of any Patent, the consent                of                Oncoscience must be obtained before taking such action or making                such                settlement, such consent not to be unreasonably withheld or                delayed. |
|-------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 9.5 | *Third                party intellectual property*.                For the avoidance of doubt Oncoscience shall be solely responsible                for                obtaining and paying for any additional licences and other rights                that may                be required to enable Oncoscience, its Affiliates or sub-licensees                to                commercialise Licensed Product in the Territory. If the sale of TheraCIM                h-R3 is found to infringe the intellectual property rights of a third                party, and results in the payment of royalties or other compensation                by                Oncoscience (or its Affiliate or sub-licensee) to the third party,                Oncoscience may reduce its royalty payments to CIMYM, the reduction                to be                in the amount of [*]% ([*] percent) of the royalties or other compensation                paid to the third party in respect of sales of Licensed Product in                the                Territory, subject to the following                conditions: |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | (a) | The                reduction shall not exceed [*]% ([*] percent) of Net Sales Value                with                respect to the country(ies) in the Territory for which payments are                being                made to the third party. For example, if in the absence of this Clause                the                royalty due from Oncoscience to CIMYM on the sale of a Licensed Product                is                [*]% ([*] percent) of Net Sales Value, the royalty following such                deduction shall not be reduced below [*]% ([*]                percent). |
|--|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | (b) | Such                reductions shall only be made where the third party liability arises                from                the use of the inventions claimed in the Licensed Patents and shall                not be                made in respect of any other inventions, improvements or other features                that Oncoscience chooses to incorporate into the Licensed                Product. |
|--|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 9.6 | *Product                names*.                Oncoscience shall be responsible for deciding, in consultation with                CIMYM,                the trade mark to be applied to the Licensed Product in the Oncoscience                Field and Territory. Oncoscience will be responsible for applying                for any                such trade mark in the Territory at its sole cost. CIMYM acknowledges                that                it has no objection against the trade mark “Theraloc”. CIMYM will be                responsible for applying for an international, non-proprietary name                (“INN”) for the Licensed Product at its sole cost. Oncoscience                acknowledges that it has no objection to the INN                “CIMAZUMAB”. |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| **10.** | **Warranties                and liability** |
|---------|---------------------------------------------|

| 10.1 | *Warranties                by CIMYM*.                CIMYM warrants that: |
|------|---------------------------------------------------------------------------|

|  | (a) | subject                to Clause 10.4, it is the owner or exclusive licensee of the Licensed                Patent Rights; and |
|--|-----|--------------------------------------------------------------------------------------------------------------------------------|

|  | (b) | it                has not done, and will not do nor agree to do during the continuation                of                this Agreement, any of the following things if to do so would be                inconsistent with the exercise by Oncoscience of the rights granted                to it                under this Agreement, namely: |
|--|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | (i) | grant                or agree to grant any rights in the Licensed Patent Rights in the                Oncoscience Field and Territory; or |
|--|-----|-------------------------------------------------------------------------------------------------------------------------------------------|

|  | (ii) | assign,                mortgage, charge or otherwise transfer any of the Licensed Patent                Rights;                and |
|--|------|------------------------------------------------------------------------------------------------------------------------------------|

|  | (c) | it                is not aware (but without having carried out any searches or                investigations) that any third party (other than CIMYM’s licensor(s)) owns                or claims any rights in the Licensed Patent                Rights. |
|--|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 10.2 | *Warranty                by Oncoscience*.                Oncoscience warrants and undertakes (a) that it has, and will continue                to                have sufficient financial and other resources to fulfil its obligations                under this Agreement, and (b) that it has obtained all necessary                authorisations from its supervisory board and investors to use such                resources and fulfil such                obligations. |
|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 10.3 | *No                other warranties* |
|------|--------------------------------------|

| 10.3.1 | Each                of Oncoscience and CIMYM acknowledges that, in entering into this                Agreement, it does not do so in reliance on any representation, warranty                or other provision except as expressly provided in this Agreement,                and any                conditions, warranties or other terms implied by statute or common                law are                excluded from this Agreement to the fullest extent permitted by                law. |
|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 10.3.2 | Without                limiting the scope of Clause 10.3.1, CIMYM does not give any warranty,                representation or undertaking:- |
|--------|----------------------------------------------------------------------------------------------------------------------------------------------|

|  | (a) | as                to the efficacy or usefulness of any of the Licensed Intellectual                Property; or |
|--|-----|-----------------------------------------------------------------------------------------------------------------|

|  | (b) | that                any of the Licensed Patent Rights is or will be valid or subsisting                or (in                the case of an application) will proceed to grant;                or |
|--|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | (c) | that                the use of any of the Licensed Intellectual Property, the manufacture,                sale or use of the Licensed Product or the exercise of any of the                rights                granted under this Agreement will not infringe any other intellectual                property or other rights of any other person;                or |
|--|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | (d) | that                the Licensed Know-how or any other information or materials communicated                or provided by CIMYM to Oncoscience under or in connection with this                Agreement will produce Licensed Product of satisfactory quality or                fit for                the purpose for which Oncoscience intended;                or |
|--|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | (e) | as                imposing any obligation on CIMYM to bring or prosecute actions or                proceedings against third parties for infringement or to defend any                action                or proceedings for revocation of any of the Licensed Patent Rights;                or |
|--|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | (f) | as                imposing any liability on CIMYM in the event that any third party                supplies                Licensed Product to customers located in the                Territory. |
|--|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 10.4 | *Indemnity                and insurance*.                Oncoscience shall indemnify and hold harmless CIMYM and (except as                otherwise provided in any Supply Agreement) CIMAB and their respective                Affiliates and their respective officers, employees, consultants,                agents                and representatives (the “Indemnitees”) against all third party Claims                which may be asserted against or suffered by any of the Indemnitees                and                which relate to: |
|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | (a) | the                use of any Delivered Items; or |
|--|-----|---------------------------------------------------|

|  | (b) | the                manufacture, distribution, sale, supply or use of the Licensed Product                or                any other products or services which incorporate any Delivered                Items, |
|--|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 10.5 | *Liability*.                Subject to Clause 10.4, but notwithstanding any other provision of                this                Agreement, no Party shall be liable to any other Party to this Agreement                in contract, tort, negligence, breach of statutory duty or otherwise                for                any loss, damage, costs or expenses of any nature whatsoever incurred                or                suffered by that other party or its Affiliates of an indirect or                consequential nature including without limitation any economic loss                or                other loss of turnover, profits, business or                goodwill. |
|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| **11.** | **Duration                and Termination** |
|---------|---------------------------------------------|

| 11.1 | *Commencement                and Termination by Expiry*.                This Agreement, and the licences granted hereunder, shall come into                effect                on the Commencement Date and, unless terminated earlier in accordance                with                this Clause 11, shall continue in force on a country by country basis                in                the Territory until the latest of: |
|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | (a) | The                date on which all the Licensed Patents have expired or been revoked                in                that country without a right of further appeal,                and |
|--|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | (b) | The                date on which any Orphan Drug Status for Licensed Product in that                country                has expired; and |
|--|-----|---------------------------------------------------------------------------------------------------------------------------------------------|

|  | (c) | The                tenth anniversary of the date of the first commercial sale of Licensed                Product in that country by Oncoscience, its Affiliate or sub-licensee                or,                if that country is part of the European Union, the tenth anniversary                of                the date of the first commercial sale of the Licensed Product in                the                European Union by Oncoscience, its Affiliate or                sub-licensee; |
|--|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 11.2 | *Early                termination* |
|------|------------------------------------|

| 11.2.1 | Oncoscience                may terminate this Agreement at any time on 90 days notice in writing                to                CIMYM. |
|--------|------------------------------------------------------------------------------------------------------------------------------------------|

| 11.2.2 | Without                prejudice to any other right or remedy, either of CIMYM or Oncoscience                may                terminate this Agreement at any time by notice in writing to the                other of                them (“Other Party”), such notice to take effect as specified in the                notice: |
|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | (a) | if                the Other Party (which in the case of Oncoscience shall include any                Affiliate or sub-licensee of Oncoscience) is in material breach of                this                Agreement and, in the case of a breach capable of remedy within 90                days,                the breach is not remedied within 90 days of the Other Party receiving                notice specifying the breach and requiring its remedy;                or |
|--|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | (b) | if                the Other Party (which in the case of Oncoscience shall include any                Affiliate or sub-licensee of Oncoscience) becomes insolvent, or if                an                order is made or a resolution is passed for the winding up of the                Other                Party (other than voluntarily for the purpose of solvent amalgamation                or                reconstruction), or if an administrator, administrative receiver                or                receiver is appointed in respect of the whole or any part of the                Other                Party’s assets or business, or if the Other Party makes any composition                with its creditors or takes or suffers any similar or analogous action                in                consequence of debt; or |
|--|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|  | (e) | if                the first Phase II clinical trial for the Licensed Product in the                Field in                the Territory has not commenced within a period of two years after                the                Commencement Date; or |
|--|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | (d) | if                the first Regulatory Approval for marketing the Licensed Product                in the                Field in the Territory is not obtained within a period of five years                after                the Commencement Date. |
|--|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 11.2.3 | CIMYM                may forthwith terminate this Agreement by giving written notice to                Oncoscience if Oncoscience or its Affiliate or sub-licensee commences                legal proceedings, or assists any third party to commence legal                proceedings, to challenge the validity of any of the                Patents. |
|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 11.2.4 | The                Parties acknowledge and agree that Oncoscience’s remedy for any breach by                CIMAB of its obligations under Clause 5 shall be as set out in Clause                5.4                or in any Supply Agreement that CIMAB and Oncoscience may execute                pursuant                to Clause 5.5. Accordingly, breach of Clause 5 shall not entitle                any Party                to terminate this Agreement. |
|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 11.3 | *Consequences                of termination* |
|------|----------------------------------------------|

| 11.3.1 | Upon                termination of this Agreement for any reason otherwise than in accordance                with Clause 11.1: |
|--------|--------------------------------------------------------------------------------------------------------------------------------|

|  | (a) | If                termination occurs afler the first commercial sale of Licensed Product,                Oncoscience and its sub-licensees shall be entitled to sell, use                or                otherwise dispose of (subject to payment of royalties under Clause                7.1 or                7.2) any unsold or unused stocks of the Licensed Product for a period                of 6                months following the date of termination; and if termination occurs                prior                to the first commercial sale of Licensed Product, Oncoscience shall                forthwith return all such stocks of Licensed Product and Licensed                Know-how                to CIMYM free of charge; |
|--|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | (b) | subject                to paragraph (a) above, Oncoscience shall no longer be licensed to                use or                otherwise exploit in any way, either directly or indirectly, any                of the                Licensed Intellectual Property; |
|--|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | (c) | subject                to paragraph (a) above, Oncoscience shall consent to the cancellation                of                any formal licence granted to it, or of any registration of it in                any                register, in relation to any of the Licensed Patent                Rights; |
|--|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | (d) | the                provisions of the following clauses shall continue in force without                limit                of time, except that the continuing obligations under Clause 4, referred                to in paragraph (i) below, shall survive for a period of 5 years                from the                termination of this Agreement: |
|--|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | (i) | Clauses                4.3 (except that Oncoscience shall not have any continuing right                to                use                Licensed Know-how or any other information received from CIMYM or                CIMAB),                4.4(a) (subject to Clause 4.5) (and no further disclosure may be                made by                Oncoscience under Clause 4.7); |
|--|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|  | (ii) | Clause                7 (in respect of sales of Licensed Product made prior to termination,                or                after termination under the first part of Clause 11.3.1(a));                and |
|--|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | (iii) | Clause                10.3 and 12; and |
|--|-------|----------------------------------------|

|  | (e) | subject                as provided in this Clause 11.3.1 and 11.3.2, and except in respect                of any                accrued rights, neither Party shall be under any further obligation                to the                other. |
|--|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 11.3.2 | Upon                termination of this Agreement for any reason otherwise than in accordance                with Clause 11.1 and at CIMYM’s request, Oncoscience shall, without charge                to, or other obligation on the part of,                CIMYM: |
|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | (a) | transfer                to CIMYM exclusively all clinical and other data relating to the                development of Licensed Product; |
|--|-----|------------------------------------------------------------------------------------------------------------------------------------------|

|  | (b) | to                the extent possible, seek to have any Regulatory Approvals (including                without limitation product licences and pricing approvals) and other                permits and applications transferred into the name of CIMYM or its                nominee; |
|--|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | (c) | grant                CIMYM an exclusive, worldwide licence, with the rights to grant                sub-licences, under all Arising Intellectual Property and any improvements                and other intellectual property owned or controlled by Oncoscience                relating to Licensed Product; and |
|--|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | (d) | grant                CIMYM or its nominee the right to continue to use any product name                that                had been applied to the Licensed Product prior to termination of                this                Agreement. |
|--|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| **12.** | **General** |
|---------|-------------|

| 12.1 | *Force                majeure*.                Neither Party shall have any liability or be deemed to be in breach                of                this Agreement for any delays or failures in performance of this                Agreement                which result from circumstances beyond the reasonable control of                that                Party, including without limitation labour disputes involving that                Party.                The Party affected by such circumstances shall promptly notify the                other                Party in writing when such circumstances cause a delay or failure                in                performance and when they cease to do                so. |
|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 12.2 | *Language                and Amendment*.                This Agreement is made in the English language and may only be amended                in                the English language in writing signed by duly authorised representatives                of the Parties. In the event of any conflict in meaning between the                English language version and any translation of this Agreement, the                English language version shall                prevail. |
|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 12.3 | *Assignment                and third party rights.* |
|------|-----------------------------------------------------|

| 12.3.1 | Subject                to Clause 12.3.2 below, no Party shall assign, mortgage, charge,                or                otherwise transfer any rights or obligations under this Agreement,                nor any                of the Patents or rights under the Patents, without the prior written                consent of the Parties. |
|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 12.3.2 | With                the prior written consent of the other Parties, a Party may assign                all its                rights and obligations under this Agreement together with its rights                in                the Patents to any company to which it transfers all or substantially                all                of its assets or business in the Field, provided that the assignee                undertakes to the other Party to be bound by and perform the obligations                of the assignor under this                Agreement. |
|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 12.4 | *Waiver*.                No failure or delay on the part of either Party to exercise any right                or                remedy under this Agreement shall be construed or operate as a waiver                thereof, nor shall any single or partial exercise of any right or                remedy                preclude the further exercise of such right or                remedy. |
|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 12.5 | *Invalid                  clauses*.                  If any provision or part of this Agreement is held to be invalid,                  amendments to this Agreement may be made by the addition or deletion                  of                  wording as appropriate to remove the invalid part or provision                  but other                  wise retain the provision and the other provisions of this Agreement                  to                  the maximum extent permissible under applicable                  law. |
|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 12.6 | *No                Agency*.                Neither Party shall act or describe itself as the agent of the other,                nor                shall it make or represent that it has authority to make any commitments                on the other’s behalf. |
|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 12.7 | *Interpretation*.                In this Agreement: |
|------|-----------------------------------------------------|

|  | (a) | the                headings are used for convenience only and shall not affect its                interpretation; |
|--|-----|-------------------------------------------------------------------------------------------------------------------|

|  | (b) | references                to persons shall include incorporated and unincorporated persons;                references to the singular include the plural and vice versa; and                references to the masculine include the                feminine; |
|--|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | (c) | references                to Clauses and Schedules mean clauses of, and schedules to, this                Agreement; |
|--|-----|----------------------------------------------------------------------------------------------------------------------|

|  | (d) | references                to any Party shall include their permitted successors and permitted                assignees; |
|--|-----|-------------------------------------------------------------------------------------------------------------------------|

|  | (e) | references                to any licence shall mean, where the context requires, a                sub-licence; |
|--|-----|----------------------------------------------------------------------------------------------------------------|

|  | (f) | where                the word “including” is used, it shall be understood as meaning “including                without limitation”; and |
|--|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | (g) | references                to the grant of “exclusive” rights shall mean that the person granting the                rights shall neither grant the same rights (in the same Field and                Territory and in respect of the same Licensed Product) to any other                person, nor exercise those rights directly to the extent that and                for as                long as the Licensed Product is within Valid Claims of unexpired                Licensed                Patent Rights or, to the extent that the Licensed Product is protected                by                Licensed Know-how that have not become known and available to the                public,                for a period of 10 years from the first commercial sale of Licensed                Product in any part of the                Territory. |
|--|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 12.8 | *Notices* |
|------|-----------|

| 12.8.1 | Any                notice to be given under this Agreement shall be in writing and shall                be                sent by first class mail, air mail or by courier, or by fax (confirmed                by                first class mail or air mail) to the address of the relevant Party                set out                at the head of this Agreement, or to the relevant fax number set                out                below, or such other address or fax number as that Party may from                time to                time notify to the other Party in accordance with this Clause 12.8.                The                fax numbers of the Parties are as                follows: |
|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| *Party*     |   | *Fax                number*     |   |
|-------------|--------|---------------------------------|--------|
|        |   |                            |   |
| CIMYM       |   | 001              905 629 4959   |   |
| CIMAB       |   | 0053              7273 3509     |   |
| Oncoscience |   | 0049              4103 1808 820 |   |

| 12.8.2 | Notices                sent as above shall be deemed to have been received three working                days                after the day of posting (in the case of inland first class mail                or                national courier), or seven working days after the date of posting                (in the                case of air mail or international courier), or on the next working                day                after transmission (in the case of fax messages, but only if a                transmission report is generated by the sender’s fax machine recording a                message from the recipient’s fax machine, confirming that the fax was sent                to the number indicated above and confirming that all pages were                successfully transmitted). |
|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 12.9 | *Law                and Jurisdiction*. The validity, construction and performance of this                Agreement shall be governed by English law. Any dispute arising out                of or                in connection with this Agreement, including any question regarding                its                existence, validity or termination, shall be referred to and finally                resolved by arbitration by a single arbitrator in London under the                Rules                of the London Court of International Arbitration (the “Rules”), which                Rules are deemed to be incorporated by reference into this clause.                The                language to be used in the arbitral proceedings shall be English.                The                arbitrator shall be chosen by the Parties or, failing agreement as                to the                choice of arbitrator within 28 days of one Party requesting that                an                arbitrator by chosen, appointed in accordance with the Rules. However,                nothing in this Agreement shall prevent a Party from seeking an interim                injunction in any court of competent                jurisdiction. |
|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 12.10 | *Further                action*. Each Party agrees to execute, acknowledge and deliver such                further instruments, and do all further similar acts, as may be necessary                or appropriate to carry out the purposes and intent of this                Agreement. |
|-------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 12.11 | *Announcements*.                Neither Party shall make any press or other public announcement concerning                any aspect of this Agreement, or make any use of the name of the                other                Party in connection with or in consequence of this Agreement, without                the                prior written consent of the other Party, except as may be required                by law                or by the rules of any stock exchange on which either Party is listed.                The                Parties shall agree a form of press release for issue on signature                of this                Agreement. |
|-------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 12.12 | *Entire                agreement*. This Agreement, including its Schedules, sets out the                entire agreement between the Parties relating to its subject matter                and                supersedes all prior oral or written agreements, arrangements or                understandings between them relating to such subject matter. The                Parties                acknowledge that they are not relying on any representation, agreement,                term or condition that is not set out in this Agreement. Nothing                in this                Agreement excludes liability for                fraud. |
|-------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 12.13 | *Third                party rights*. Each of the persons identified as Indemnitees in Clause                10.4 may in his own right enforce the provisions of those respective                Clauses. Except as provided in the previous sentence of this Clause                12.12,                this Agreement is not made for the benefit of, nor shall any of its                provisions be enforceable by, any person other than the parties to                this                Agreement and their respective successors and permitted                assignees. |
|-------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 12.14 | *Non-compete*.                Oncoscience warrants, represents, acknowledges and agrees, in respect                of                it and its Affiliates that: |
|-------|------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | (a) | they                do not have any interest in any technology that competes with the                Licensed                Intellectual Property, nor is any of them engaged in any research                or                development activities with respect to any product that would compete                with                the Licensed Products; and |
|--|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | (b) | for                as long as this Agreement remains in force, they will not enter into                any                agreement with any Person other than CIMAB or CIMYM for the development                or                marketing of any product that is, or contains, (i) any other                anti-EGF-receptor inhibitor, (ii) any product or component or sequence                of                EGF-R, EGF-R ligands, or any small tyrosine kinase                inhibitor. |
|--|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 12.15 | *Amendment                and Restatement*. The Original Agreement is hereby terminated. This                Agreement supersedes, and amends and restates the Original                Agreement. |
|-------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

**Agreed**

**CIMYM,      Inc.**

| [ILLEGIBLE]        |   |                 |
|------------------------------|--------|---------------------------|
| signed                       |   | signed                    |
|                         |   |                      |
| [ILLEGIBLE]                  |   |                 |
| print                name    |   | print                name |
|                         |   |                      |
| Chair              & CEO |   |                 |
| title                        |   | title                     |
|                         |   |                      |
| Aug              27/2007     |   |                 |
| date                         |   | date                      |

**CIMAB      S.A.**

| [ILLEGIBLE]                  |   |                 |
|------------------------------|--------|---------------------------|
| signed                       |   | signed                    |
|                         |   |                      |
| [ILLEGIBLE]                  |   |                 |
| print                name    |   | print                name |
|                         |   |                      |
| General              Manager |   |                 |
| title                        |   | title                     |
|                         |   |                      |
| 14/09/2007                   |   |                 |
| date                         |   | date                      |
|                         |   |                      |
|                              |   |                      |

**Oncoscience      AG**

| /s/              F. Bach  |   |            |
|--------------------------------|--------|---------------------------|
| signed                         |   | signed                    |
|                           |   |                      |
| F.              BACH           |   |            |
| print                name      |   | print                name |
|                           |   |                      |
| CEO                            |   |            |
| title                          |   | title                     |
|                           |   |                      |
| [ILLEGIBLE]                    |   |            |
| date                           |   | date                      |
|                           |   |                      |
|                                |   |                      |

----

**Schedule      1**

*Licensed      Patent Rights*

*Monoclonal Antibodies      Recognizing the Epidermal Growth Factor Receptor, Cells and Methods for Their      Production and Compositions Containing Them (mR3)*

| **Country** |   | **Filing****Date**  |   | **Serial                  No.** |   | **PubIn****Date**   |   | **Publn****No.** |   | **Issue****Date** |   | **Patent****No.** |
|-------------|--------|---------------------|--------|---------------------------------|--------|---------------------|--------|------------------|--------|-------------------|--------|-------------------|
| Europe1     |   | 18 Aug 93 |   | 93202428.4                      |   | 09 Mar 94 |   | 586002           |   | Granted           |   | 586002            |

**Humanized      and Chimeric Antibodies for EGF Receptor Used in Diagnosis and Therapy of      Tumours (hR3)**

| **Country** |   | **Filing****Date2** |   | **Serial                  No.** |   | **Publn****Date**   |   | **Publn****No.** |   | **Issue****Date** |   | **Patent****No.** |
|-------------|--------|---------------------|--------|---------------------------------|--------|---------------------|--------|------------------|--------|-------------------|--------|-------------------|
| Europe*     |   | 15 Nov 95 |   | 95203126.8                      |   | 22 May 96 |   | 712,863          |   | Granted           |   | 712,863           |

----

----

**Schedule      2**

*Licensed      Know-how*

----

**Schedule      3**

*Initial      Development and Commercialisation Plan*

|  | 1. | A                registration study in glioma. It is provisionally estimated that                enrolment                will be in the range of 80 – 100                patients. |
|--|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | 2. | A                pilot study in paediatric brain tumours. It is provisionally estimated                that enrolment will be in the range of 6 – 10                patients. |
|--|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | 3. | A                registration study in paediatric brain tumours. It is provisionally                estimated that enrolment will be in the range of 60 – 80                patients. |
|--|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | 4. | A                pilot study in metastatic pancreatic cancer. It is provisionally                estimated                that enrolment will be in the range of 14 – 20                patients. |
|--|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | 5. | Application                for Orphan Drug Status for the Product with the                EMEA. |
|--|----|-------------------------------------------------------------------------------------------------|

*votum*

----

**Schedule      4**

*Appointment      of expert*

----